| __timestamp | Eli Lilly and Company | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4733600000 | 79696000 |
| Thursday, January 1, 2015 | 4796400000 | 93236000 |
| Friday, January 1, 2016 | 5243900000 | 150842000 |
| Sunday, January 1, 2017 | 5281800000 | 150643000 |
| Monday, January 1, 2018 | 5051200000 | 150252000 |
| Tuesday, January 1, 2019 | 5595000000 | 140804000 |
| Wednesday, January 1, 2020 | 6085700000 | 34236000 |
| Friday, January 1, 2021 | 7025900000 | 35672000 |
| Saturday, January 1, 2022 | 7190800000 | 66607000 |
| Sunday, January 1, 2023 | 9313400000 | 76363000 |
| Monday, January 1, 2024 | 14271000000 | 79048000 |
Cracking the code
In the competitive world of pharmaceuticals, innovation is key. Eli Lilly and Company and Halozyme Therapeutics, Inc. are two giants in the industry, each with a unique approach to research and development (R&D). Over the past decade, Eli Lilly has consistently outpaced Halozyme in R&D spending, investing nearly 60 times more on average. From 2014 to 2023, Eli Lilly's R&D expenses grew by approximately 97%, peaking in 2023 with a staggering $9.3 billion. In contrast, Halozyme's investment remained relatively stable, with a slight dip in 2020. This disparity highlights Eli Lilly's aggressive strategy to lead in innovation, while Halozyme maintains a more conservative approach. As the pharmaceutical landscape evolves, these investment strategies will undoubtedly shape the future of healthcare innovation.
Research and Development Investment: Eli Lilly and Company vs Takeda Pharmaceutical Company Limited
Comparing Innovation Spending: Eli Lilly and Company and Axsome Therapeutics, Inc.
Research and Development Investment: Eli Lilly and Company vs Alpine Immune Sciences, Inc.
Analyzing R&D Budgets: Eli Lilly and Company vs Ultragenyx Pharmaceutical Inc.
Comparing Innovation Spending: Eli Lilly and Company and CRISPR Therapeutics AG
Eli Lilly and Company vs ImmunityBio, Inc.: Strategic Focus on R&D Spending
Eli Lilly and Company or HUTCHMED (China) Limited: Who Invests More in Innovation?
Who Prioritizes Innovation? R&D Spending Compared for Johnson & Johnson and Halozyme Therapeutics, Inc.
Research and Development Investment: Sanofi vs Halozyme Therapeutics, Inc.
Insmed Incorporated vs Halozyme Therapeutics, Inc.: Strategic Focus on R&D Spending
Research and Development: Comparing Key Metrics for Halozyme Therapeutics, Inc. and Rhythm Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Halozyme Therapeutics, Inc. and Vericel Corporation